Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

InVivo's Day Has Arrived

On April 28, 2014, InVivo Therapeutics (NASDAQ:NVIV) announced something that investors have been waiting on for a very long time - the biocompatible polymer scaffolding has finally entered human clinical trials for the treatment of acute spinal cord injury. We remind investors that implantation of the Neuro-Spinal Scaffold ("NSS") device in preclinical rodent and primate studies resulted in functional recovery for previously paralyzed animals. Recall some of the impressive videos the company made available in 2011 and 2012 from these studies. The company is hoping these results transition over to humans with the start of this potential revolutionary trial.

InVivo's NSS is made of a porous bioresorbable polymer scaffold comprised of poly ((lactic-co-glycolic acid)-co-poly-(L-lysine)), or PLGA-PLL. The device...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details